195 related articles for article (PubMed ID: 31704974)
21. The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands.
van der Heiden-van der Loo M; Siesling S; Wouters MW; van Dalen T; Rutgers EJ; Peeters PH
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S522-8. PubMed ID: 25986872
[TBL] [Abstract][Full Text] [Related]
22. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
23. Identification of potentially druggable molecular alterations in skin adnexal malignancies.
Cavalieri S; Busico A; Capone I; Conca E; Dallera E; Quattrone P; Licitra L; Pruneri G; Bossi P; Perrone F
J Dermatol; 2019 Jun; 46(6):507-514. PubMed ID: 31038235
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
25. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
[TBL] [Abstract][Full Text] [Related]
26. Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
Michieletto S; Saibene T; Evangelista L; Barbazza F; Grigoletto R; Rossi G; Ghiotto C; Bozza F
Breast; 2014 Feb; 23(1):19-25. PubMed ID: 24189101
[TBL] [Abstract][Full Text] [Related]
27. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
29. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
Chen X; Fan Y; Xu B
Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
[TBL] [Abstract][Full Text] [Related]
30.
Yamashita H; Ishida N; Hatanaka Y; Hagio K; Oshino T; Takeshita T; Kanno-Okada H; Shimizu AI; Hatanaka KC; Matsuno Y
Anticancer Res; 2020 Feb; 40(2):645-652. PubMed ID: 32014905
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
32. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
[TBL] [Abstract][Full Text] [Related]
33. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
34. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
35. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
36. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
37. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
38. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
[TBL] [Abstract][Full Text] [Related]
39. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
40. PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.
Wang Y; Chen H; Jiao X; Wu L; Yang Y; Zhang J; Wu L; Liu C; Zhuo N; Li S; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Lu Z; Zhang H; Shen L
Cancer Immunol Immunother; 2022 Jan; 71(1):111-120. PubMed ID: 34028566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
